| UHC Surest Medical and Drug | Enjaymo® (Sutimlimab-Jome) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | FcRn Blockers – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Givlaari® (Givosiran) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Lemtrada® (Alemtuzumab) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Niktimvo™ (Axatilimab-Csfr) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Parsabiv® (Etelcalcetide) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Somatostatin Analogs – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Tzield® (Teplizumab-Mzwv) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Complement C5 Inhibitors – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Enjaymo® (Sutimlimab-Jome) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |